|
Latest Reports
|
| Date |
Description |
Country |
Analyst |
Download |
|
|
| 10-Apr-2024 |
Chemicals/Pharma Exim trends - March 2024: Reaffirms the reversal of global Chemical demand |
India |
Surya Patra |
 |
| 01-Apr-2024 |
Pharmaceuticals Q4FY24 preview - Ramp up in gRevlimid to drive earnings growth; Top Results Pick - ARBP (+ve) and BIOS (-ve): |
India |
Surya Patra |
|
| 12-Mar-2024 |
Chemicals/Pharma Exim trends - February 2024; Upgrade to BUY - ARTO, SRF & VO; Re-iterate SELL - CIPLA, LUPIN, IPCA |
India |
Surya Patra |
|
| 04-Mar-2024 |
Aurobindo Pharma - Multiple growth levers in place; Buy with raised TP of Rs 1400 |
India |
Surya Patra |
|
| 15-Feb-2024 |
IPCA Laboratories - Unichem integration weighs on margins; Maintain SELL with TP Rs 910 |
India |
Surya Patra |
|
| 12-Feb-2024 |
Aurobindo Pharma - Multiple triggers boost earning visibility; Maintain BUY with raised TP of Rs 1300 |
India |
Surya Patra |
|
| 11-Feb-2024 |
Divis Laboratories - Opportunities galore but margins pressure continues; Remain Neutral with TP Rs 3300 |
India |
Surya Patra |
|
| 10-Feb-2024 |
Zydus Lifesciences Ltd - Margin surprised +vely; Robust 4Q likely; Maintain BUY with raised TP Rs 880 |
India |
Surya Patra |
|
| 09-Feb-2024 |
Biocon - Weak Q3; Progress on pipeline is key monitorable; Maintain Neutral with lowered TP Rs 260 |
India |
Surya Patra |
|
| 08-Feb-2024 |
Lupin - Spiriva as well as pipeline benefits already priced in; SELL with TP Rs 1300: |
India |
Surya Patra |
|
| 01-Feb-2024 |
Sun Pharma - In line performance and visible triggers priced-in; Downgrade to Neutral with TP Rs 1370 |
India |
Surya Patra |
|
| 30-Jan-2024 |
Dr Reddys Laboratories - Powered by gRevlimid & steady growth in base biz; Maintained BUY with TP Rs 6500 |
India |
Surya Patra |
|
| 28-Jan-2024 |
Cipla Ltd - Drug launch delays & concentration risk are worrisome; Re-iterate SELL with TP Rs 1150 |
India |
Surya Patra |
|
| 04-Jan-2024 |
Pharmaceuticals - Q3FY24 Preview: US growth supportive; Key Ideas - Positive: ARBP, SUNP / Negative: CIPLA, BIOS |
India |
Surya Patra |
|
| 04-Jan-2024 |
Pharmaceuticals - Q3FY24 Preview: US growth supportive; Key Ideas - Positive: ARBP, SUNP / Negative: CIPLA, BIOS |
India |
Surya Patra |
|
| 15-Nov-2023 |
IPCA Laboratories - Unichem integration dilutes earnings despite synergies; Re-iterate SELL with TP Rs 790 |
India |
Surya Patra |
|
| 11-Nov-2023 |
Vinati Organics Ltd - Concern of moderating margins remain intact; Maintain Neutral with lowered TP of Rs 1750 |
India |
Surya Patra |
|
| 10-Nov-2023 |
Aurobindo Pharma - Foresee a qualitative upgrade in its business model; Upgrade to BUY with TP Rs 1100: |
India |
Surya Patra |
|
| 07-Nov-2023 |
Divis Laboratories - Q2 Margin miss despite strong custom synthesis sales concerns us; Maintain NEUTRAL with TP Rs 3100 |
India |
Surya Patra |
|
| 02-Nov-2023 |
Sun Pharma - Core operating performance remains strong; Maintain BUY with the pre-fixed TP of Rs 1250 |
India |
Surya Patra |
|
| 30-Oct-2023 |
Cipla - Strong Q2 but visible triggers priced-in; Maintain NEUTRAl with Pre-fixed TP of Rs 1070 |
India |
Surya Patra |
|
| 29-Oct-2023 |
Dr Reddys Laboratories - Powered by gRevlimid benefits & steady growth in base biz; Maintain BUY with TP Rs 6200 |
India |
Surya Patra |
|
| 05-Oct-2023 |
Pharma Q2FY24 Preview: Improved US neutralises slowing India formulations; Key Top Q2FY24 result picks: Positive: ARBP, ZYDUSLIF, DRRD |
India |
Surya Patra |
|
| 16-Aug-2023 |
Vinati Organics - Weak ATBS demand hurts FY24; Maintain NEUTRAL with pre-fixed TP of Rs 1900 |
India |
Surya Patra |
|
| 16-Aug-2023 |
Aurobindo Pharma - Strong margin outlook but largely priced in; Downgrade to NEUTRAL with TP Rs 900: |
India |
Surya Patra |
|
|
|